The purpose of respiratory support is to maintain adequate ventilation and oxygenation. Consequently, ensuring adequate alveolar ventilation is essential for expelling carbon dioxide produced in the human body. Currently, during invasive or noninvasive ventilatory support, minute ventilation is manipulated to ensure adequate alveolar ventilation. For patients with COPD exacerbations, noninvasive ventilation (NIV) has become the preferred primary modality for respiratory support because it both enhances inspiratory tidal volume and maintains adequate alveolar ventilation. Because of poor mask tolerance, however, NIV is sometimes inapplicable.
High-flow nasal cannula (HFNC) oxygen delivery has been gaining attention as an alternative means of respiratory support for critically ill patients. In the literature, this technique has also been called mini-CPAP, transnasal insufflation, nasal high flow, nasal high-flow ventilation, high-flow therapy, and high-flow nasal cannula oxygen therapy. Here, the term HFNC is used. The apparatus comprises an air-oxygen blender, an active heated humidifier, a single heated circuit, and a nasal cannula. The F IO 2 is set in the air-oxygen blender from 0.21 to 1.0 with flows of up to 60 L/min. The gas is heated and humidified with the active humidifier and delivered through the heated circuit. Another big difference between NIV and HFNC is the interface. Although interfaces for NIV increase anatomical dead space, HFNC actually decreases dead space. Because neither inspiratory push nor expiratory pull is effective in such an open circuit, HFNC cannot actively enhance tidal volume. Even so, it helps patients with COPD mainly by decreasing anatomical dead space and improving alveolar ventilation.
In clinical trials with subjects with COPD, 1 response to HFNC has been varied. For some subjects, it has been shown to reduce breathing frequency and, in some cases, to decrease P aCO 2 . Tested using an unloaded bicycle ergometer, compared with spontaneous breathing, 2 HFNC has also increased the exercise capacity of some subjects, who show improved oxygenation. HFNC has proved to be an innovative and unique therapy for some types of hypercapnic respiratory failure.
Maintaining adequate oxygenation depends on properly managing F IO 2 and PEEP. For hypoxemic patients, provision of supplemental oxygen has long been the frontline therapy. Oxygen is generally provided via a face mask or nasal cannula, with oxygen delivery limited to no more than 15 L/min. Using conventional methods, when there are large differences between patient inspiratory flow and delivered flow, F IO End-expiratory lung volume has been evaluated with electrical lung impedance tomography: it was greater with HFNC than with low-flow oxygen therapy. 4 For patients with hypoxemic respiratory failure, how well does cannula delivery work in maintaining stable F IO 2 and positive pharyngeal pressure? From the reported physiological effects of HFNC, although it has been effective for mild-to-moderate hypoxemic respiratory failure, 5 it has not been recommended for severe hypoxemic respiratory failure because it is not possible to ensure sufficient positive pharyngeal pressure. Sztrymf et al 6 evaluated HFNC in subjects with mild-to-moderate respiratory failure in a cardiothoracic care unit: HFNC treatment was successful for 26 (68%) of the 38 subjects who received it. In another cardiothoracic ICU, Parke et al 7 randomly assigned subjects with mild-to-moderate respiratory failure to HFNC or face mask delivery. Only 10% of the HFNC group needed NIV, whereas 44% of the face mask group required escalated therapeutic ventilation. Maggiore et al 8 randomly assigned subjects after extubation to HFNC or air-entrain-RESPIRATORY CARE • FEBRUARY 2015 VOL 60 NO 2ment mask. HFNC resulted in better oxygenation and a lower re-intubation rate. Even though we lack evidence from large randomized controlled trials (RCTs), the results from these studies suggest that innovative HFNC is an effective therapy for mild-to-moderate hypoxemic respiratory failure.
There have been few reports of HFNC use in severe acute respiratory failure. Rello et al 9 applied HFNC during acute hypoxemic respiratory failure attributable to influenza A/H1N1virus. Five of the 25 subjects in this study received conventional oxygen administration. For the remaining 20 subjects, all of whom initially received supplemental oxygen at flows of Ͼ 9 L/min, it was not possible to maintain S pO 2 above 92%. HFNC was effective for 9 of the 20 subjects, who thus avoided intubation, which the remaining 11 subjects subsequently required. These results suggest that it could be initially worthwhile trying HFNC for patients with acute respiratory infection syndrome. Innovative HFNC may well be an effective modality for early treatment of adults with severe acute respiratory failure. Of course, further study is needed to establish efficacies and indicators for patients in this category, and we eagerly await the results of both the FLORALI (High Flow Oxygen Therapy for Resuscitation of Patients with Acute Lung Injury) study, which has completed subject enrollment, 10 and the OPERA trial, which is evaluating how well HFNC prevents postextubation hypoxemia after abdominal surgery. 11 The results of these RCTs will provide the kind of rigorous evidence we need to confidently guide clinical choices.
Even so, the results of large RCTs are not always as useful as we might anticipate. Single-center studies may also help us toward great improvements in practice. Close observation can provide well-founded useful conclusions: in this issue of RESPIRATORY CARE, Messika et al 12 report on the effectiveness of HFNC for subjects with ARDS, finding it effective for 26 of 45 subjects. Despite its limitations of being an observational study, and despite leaving open issues such as indications for HFNC, timing for start of HFNC, and criteria for escalating treatment beyond HFNC, the study suggests that innovative HFNC therapy is a promising modality for early treatment of adults with severe acute respiratory failure. It is time to reconsider our reliance on huge RCTs to provide conclusive evidence of the suitability of new treatments for each type of patient.
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